This led to the development and evaluation of drugs like trastuzumab, which targeted the HER2 protein in breast cancer cells, and lapatinib, which was a tyrosine kinase inhibitor that could target both HER2 and EGFR proteins. This evidence concerns the gene EGFR and breast carcinoma.